The Food and Drug Administration has placed a clinical hold on Johnson & Johnson's nerve growth factor inhibitor drug fulranumab due to a possible association with a condition that could lead to a need for total joint replacements, according to a Reuters news report.
The drug was developed to block nerve growth factor, a protein associated with pain. Johnson & Johnson's fulranumab was not the only product to be placed on clinical hold due to a possible link to a bone disorder that would require a total joint replacement. Regeneron Pharmaceuticals has also had its pain drug for osteoarthritis put on hold.
Read the news report about the FDA's hold on Johnson & Johnson's fulranumab.
Read other coverage about the FDA:
- New Test Measuring DNA Methylation Levels Could Help Detect CRC
- Pharmaceutical Companies Submit Pain Management Drug to FDA
- FDA Accepts Drug Application for Postsurgical Pain Management
The drug was developed to block nerve growth factor, a protein associated with pain. Johnson & Johnson's fulranumab was not the only product to be placed on clinical hold due to a possible link to a bone disorder that would require a total joint replacement. Regeneron Pharmaceuticals has also had its pain drug for osteoarthritis put on hold.
Read the news report about the FDA's hold on Johnson & Johnson's fulranumab.
Read other coverage about the FDA:
- New Test Measuring DNA Methylation Levels Could Help Detect CRC
- Pharmaceutical Companies Submit Pain Management Drug to FDA
- FDA Accepts Drug Application for Postsurgical Pain Management